Catubig, Mercy S.
HRN: 01-63-74 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/28/2022
CO-AMOXICLAV 625MG (TAB)
07/28/2022
08/03/2022
PO
625mg
BID
Acute Cystitis
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes